StockVS

Cryoport, Inc. (CYRX) Stock Analysis

Industrials

Cryoport, Inc.

$13.96

$-0.04 (-0.29%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

Cryoport, Inc. operates within the Industrials sector, specifically focusing on the Integrated Freight & Logistics industry, where it delivers specialized temperature-controlled supply chain solutions for the biopharma, pharma, animal health, and reproductive medicine markets globally. The company's core operations, categorized under its Life Sciences Services segment, encompass temperature-controlled logistics, biostorage, bioservices, and cryopreservation services designed to preserve sensitive biological materials during transportation and storage. As a mid-sized entity in this specialized niche, the company maintains a market capitalization of $421.08M while employing 684 individuals to support its logistical network. With annual revenue reaching $176.18M, these financial figures indicate that Cryoport, Inc. has established a significant operational footprint, though the market cap suggests it is currently valued below a large-cap threshold, reflecting the early-stage or turnaround nature often associated with companies in the biopharma logistics sector that are yet to achieve consistent profitability.

Financial Health

The company reported a revenue of $176.18M for the trailing twelve months, yet it recorded a net income of $-41,969,000 and an EBITDA of $-3,916,000, revealing a substantial disparity between top-line growth and bottom-line profitability. This gap between revenue and net income indicates a cost structure where operating expenses, likely driven by the capital-intensive nature of cold-chain logistics and the high costs of maintaining specialized storage facilities, significantly erode earnings before interest and taxes. Free cash flow stood at $-396,125, which implies that the company is currently burning cash rather than generating liquidity, thereby limiting its financial flexibility to fund operations without external capital injections. Despite these operational losses, the company holds a cash balance of $411.21M against total debt of $230.72M, resulting in a debt-to-equity ratio of 45.90. While the absolute debt level is lower than the cash reserve, the high debt-to-equity ratio suggests a leveraged balance sheet where equity is relatively small compared to the debt burden. The current ratio is 2.17, indicating that the company possesses 2.17 dollars of current assets for every dollar of current liabilities, which points to strong short-term liquidity and an ability to meet obligations as they come due. Return on Equity is -7.5% and Return on Assets is -2.7%, metrics that reveal that management has not yet been effective in generating positive returns on the capital invested by shareholders or the assets utilized for operations.

Valuation Assessment

The P/E Ratio (TTM) is listed as N/A due to negative earnings, while the Forward P/E is -13.07, a negative figure that implies the market expects earnings to remain negative or requires significant time to turn profitable. The price-to-book ratio is 0.91, indicating that the stock is trading at approximately 91% of its book value, which suggests the market is pricing the company slightly below its net asset value rather than applying a premium for its growth prospects. Alternative valuation metrics provide further context; the price-to-sales ratio is 2.39 and the EV/EBITDA is -71.78, suggesting that valuation is currently being driven by revenue multiples rather than earnings power, a common approach for growth-oriented or turnaround logistics firms. The stock has a 52-week high of $11.45 and a 52-week low of $4.63; given the forward P/E context, the current price sits in a volatile range that reflects investor caution regarding the path to profitability. The beta value is 1.74, which indicates that the stock is significantly more volatile than the broader market, moving with an amplified magnitude relative to general market swings.

Growth & Income

Revenue growth year-over-year is 9.6%, whereas earnings growth is N/A due to the current net loss, illustrating that the company is prioritizing top-line expansion and market share acquisition over immediate profitability. As a non-dividend payer, the company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings, if any, and cash reserves are retained within the business to fund operations and growth initiatives rather than being returned to shareholders. The absence of a dividend payout confirms that the company reinvests its limited cash flows and existing cash reserves into its logistical infrastructure and service offerings to capture growth in the temperature-controlled supply chain market. Overall, Cryoport, Inc. presents a growth-oriented profile characterized by strong revenue expansion but lacks an income component, relying entirely on potential future earnings growth to drive shareholder value rather than current cash distributions or capital appreciation from a dividend yield.

Peer Comparison

Cryoport, Inc. (CYRX) operates in the Integrated Freight & Logistics industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cryoport, Inc. CYRX $703.62M N/A
FedEx Corporation FDX $95.44B 21.4
United Parcel Service, Inc. UPS $86.68B 16.5
J.B. Hunt Transport Services, Inc. JBHT $25.24B 41.5

The Integrated Freight & Logistics industry average P/E ratio is 22.6x. Cryoport, Inc. trades at a P/E of N/A.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Cryoport, Inc.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.

Visit website →

Key Statistics

Market Cap
$703.62M
P/E Ratio
N/A
52-Week High
$14.36
52-Week Low
$5.31
Avg Volume
559.55K
Beta
1.75

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
NASDAQ
Country
United States
Employees
684